Invasive fungal infections in humans are common in people with compromised immune systems and are difficult to treat, resulting in high mortality. Amphotericin B (AmB) is one of the main antifungal drugs available to treat these infections. AmB binds with plasma membrane ergosterol, causing leakage of cellular ions and promoting cell death. The increasing use of available antifungal drugs to combat pathogenic fungal infections has led to the development of drug resistance. AmB resistance is not very common and is usually caused by changes in the amount or type of ergosterol or changes in the cell wall. Intrinsic AmB resistance occurs in the absence of AmB exposure, whereas acquired AmB resistance can develop during treatment. However, clinical resistance arises due to treatment failure with AmB and depends on multiple factors such as the pharmacokinetics of AmB, infectious fungal species, and host immune status. Candida albicans is a common opportunistic pathogen that can cause superficial infections of the skin and mucosal surfaces, thrush, to life-threatening systemic or invasive infections. In addition, immunocompromised individuals are more susceptible to systemic infections caused by Candida, Aspergillus, and Cryptococcus. Several antifungal drugs with different modes of action are used to treat systemic to invasive fungal infections and are approved for clinical use in the treatment of fungal diseases. However, C. albicans can develop a variety of defenses against antifungal medications. In fungi, plasma membrane sphingolipid molecules could interact with ergosterol, which can lead to the alteration of drug susceptibilities such as AmB. In this review, we mainly summarize the role of sphingolipid molecules and their regulators in AmB resistance.
Get full access to this article
View all access options for this article.
References
1.
LopesJP, LionakisMS. Pathogenesis and virulence of Candida albicans. Virulence, 2022; 13(1):89–121; doi: 10.1080/21505594.2021.2019950
HaniU, ShivakumarH, VaghelaR, et al.Candidiasis: A fungal infection—Current challenges and progress in prevention and treatment. Infect Disord Drug Targets, 2015; 15(1):42–52; doi: 10.2174/1871526515666150320162036
TaeiM, ChadeganipourM, MohammadiR. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC Res Notes, 2019; 12(1):779; doi: 10.1186/s13104-019-4811-1
Hay RJ. The management of superficial candidiasis. J Am Acad Dermatol, 1999; 40(6 Pt 2):S35–S42; doi: 10.1016/S0190-9622(99)70396-8
10.
KristancL, BožičB, Jokhadar ŠZ, et al. The pore-forming action of polyenes: From model membranes to living organisms. Biochim Biophys Acta Biomembr, 2019; 1861(2):418–430; doi: 10.1016/j.bbamem.2018.11.006
11.
Thomas PA. Fungal infections of the cornea. Eye (Lond), 2003; 17(8):852–862; doi: 10.1038/sj.eye.6700557
12.
AustinA, LietmanT, Rose-NussbaumerJ. Update on the management of infectious keratitis. Ophthalmology, 2017; 124(11):1678–1689; doi: 10.1016/j.ophtha.2017.05.012
13.
HoffmanJJ, BurtonMJ, LeckA. Mycotic keratitis—A global threat from the filamentous fungi. J Fungi (Basel), 2021; 7(4):273; doi: 10.3390/jof7040273
14.
LyuX, ZhaoC, YanZM, et al.Efficacy of nystatin for the treatment of oral candidiasis: A systematic review and meta-analysis. Drug Des Devel Ther, 2016; 10:1161–1171; doi: 10.2147/DDDT.S100795
15.
ClevenberghP, JacobsF, KentosA, et al.Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: Report of 30 courses. Clin Microbiol Infect, 1998; 4(4):192–198; doi: 10.1111/j.1469-0691.1998.tb00668.x
16.
TollemarJ, KlingsporL, RingdénO. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect, 2001; 7(Suppl 2):68–79; doi: 10.1111/j.1469-0691.2001.tb00012.x
17.
GallisHA, DrewRH, PickardWW. Amphotericin B: 30 Years of clinical experience. Rev Infect Dis, 1990; 12(2):308–329; doi: 10.1093/clinids/12.2.308
JamborWP, SteinbergBA, SuydamLO. Amphotericins A and B: Two new antifungal antibiotics possessing high activity against deep-seated and superficial mycoses. Antibiot Annu, 1955; 3:574–578.
20.
StillerET, VandeputteJ, WachtelJL. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. II. The isolation and properties of the crystalline amphotericins. Antibiot Annu, 1955; 3:587–591.
21.
BaginskiM, GariboldiP, BruniP, et al.Conformational analysis of amphotericin B. Biophys Chem, 1997; 65(2–3):91–100; doi: 10.1016/S0301-4622(96)02265-X
22.
CzubJ, BaginskiM. Modulation of amphotericin B membrane interaction by cholesterol and ergosterol—A molecular dynamics study. J Phys Chem B, 2006; 110(33):16743–16753; doi: 10.1021/jp061916g
23.
Szlinder-RichertJ, MazerskiJ, CybulskaB, et al.MFAME, N-methyl-N-D-fructosyl amphotericin B methyl ester, a new amphotericin B derivative of low toxicity: Relationship between self-association and effects on red blood cells. Biochim Biophys Acta Gen Subj, 2001; 1528(1):15–24; doi: 10.1016/S0304-4165(01)00166-0
24.
BaginskiM, ResatH, McCammonJA. Molecular properties of amphotericin B membrane channel: A molecular dynamics simulation. Mol Pharmacol, 1997; 52(4):560–570; doi: 10.1124/mol.52.4.560
25.
MiñonesJ, Dynarowicz-Ła̧tkaP, CondeO, et al.Interactions of amphotericin B with saturated and unsaturated phosphatidylcholines at the air/water interface. Colloids Surf B Biointerfaces, 2003; 29(2–3):205–215; doi: 10.1016/S0927-7765(02)00220-5
26.
BrajtburgJ, PowderlyWG, KobayashiGS, et al.Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother, 1990; 34(2):183–188; doi: 10.1128/AAC.34.2.183
27.
IwakiT, IefujiH, HiragaY, et al.Multiple functions of ergosterol in the fission yeast Schizosaccharomyces pombe. Microbiology (N Y), 2008; 154(3):830–841; doi: 10.1099/mic.0.2007/011155-0
28.
HannichJT, UmebayashiK, RiezmanH. Distribution and functions of sterols and sphingolipids. Cold Spring Harb Perspect Biol, 2011; 3(5):a004762; doi: 10.1101/cshperspect.a004762
29.
GrayKC, PalaciosDS, DaileyI, et al.Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A, 2012; 109(7):2234–2239; doi: 10.1073/pnas.1117280109
30.
AndersonTM, ClayMC, CioffiAG, et al.Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol, 2014; 10(5):400–406; doi: 10.1038/nchembio.1496
RomeroEA, ValdiviesoE, CohenBE. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. J Membr Biol, 2009; 230(2):69–81; doi: 10.1007/s00232-009-9187-z
33.
RamosH, ValdiviesoE, GamargoM, et al.Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol, 1996; 152(1):65–75; doi: 10.1007/s002329900086
34.
PalaciosDS, DaileyI, SiebertDM, et al.Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proc Natl Acad Sci U S A, 2011; 108(17):6733–6738; doi: 10.1073/pnas.1015023108
35.
SimonsK, SampaioJL. Membrane organization and lipid rafts. Cold Spring Harb Perspect Biol, 2011; 3(10):a004697; doi: 10.1101/cshperspect.a004697
36.
Ha̧c-WydroK, Dynarowicz-Ła̧tkaP, GrzybowskaJ, et al.Interactions of amphotericin B derivative of low toxicity with biological membrane components—The Langmuir monolayer approach. Biophys Chem, 2005; 116(1):77–88; doi: 10.1016/j.bpc.2005.03.001
37.
WalshTJ, PizzoA. Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol Infect Dis, 1988; 7(4):460–475; doi: 10.1007/BF01962595
38.
Sokol-AndersonML, BrajtburgJ, MedoffG. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis, 1986; 154(1):76–83; doi: 10.1093/infdis/154.1.76
39.
Mesa-ArangoAC, Trevijano-ContadorN, RománE, et al.The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother, 2014; 58(11):6627–6638; doi: 10.1128/AAC.03570-14
40.
FerreiraGF, BaltazarLM, Alves SantosJR, et al.The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii. J Antimicrob Chemother, 2013; 68(8):1801–1811; doi: 10.1093/jac/dkt114
41.
PhillipsAJ, SudberyI, RamsdaleM. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci U S A, 2003; 100(Suppl 2):14327–14332; doi: 10.1073/pnas.2332326100
42.
ShekhovaE, KniemeyerO, BrakhageAA. Induction of mitochondrial reactive oxygen species production by itraconazole, terbinafine, and amphotericin B as a mode of action against Aspergillus fumigatus. Antimicrob Agents Chemother, 2017; 61(11):e00978-17; doi: 10.1128/AAC.00978-17
43.
DelattinN, CammueBP, ThevissenK. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem, 2014; 6(1):77–90; doi: 10.4155/fmc.13.189
44.
Lamy-FreundMT, FerreiraVFN, SchreierS. Mechanism of inactivation of the polyene antibiotic amphotericin B evidence for radical formation in the process of autooxidation. J Antibiot (Tokyo), 1985; 38(6):753–757; doi: 10.7164/antibiotics.38.753
45.
LiangT, ChenW, YangX, et al.The elevated endogenous reactive oxygen species contribute to the sensitivity of the amphotericin b-resistant isolate of Aspergillus flavus to triazoles and echinocandins. Front Microbiol, 2021; 12:680749; doi: 10.3389/fmicb.2021.680749
46.
Sangalli-LeiteF, ScorzoniL, Mesa-ArangoAC, et al.Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect, 2011; 13(5):457–467; doi: 10.1016/j.micinf.2011.01.015
47.
CarolusH, PiersonS, LagrouK, et al.Amphotericin B and other polyenes—Discovery, clinical use, mode of action and drug resistance. J Fungi (Basel), 2020; 6(4):321; doi: 10.3390/jof6040321
48.
DonowitzGR, MakiDG, CrnichCJ, et al.Infections in the neutropenic patient—New views of an old problem. Hematology Am Soc Hematol Educ Program, 2001; 113–139; doi: 10.1182/asheducation-2001.1.113
49.
HerbrechtR, Natarajan-AméS, NivoixY, et al.The lipid formulations of amphotericin B. Expert Opin Pharmacother, 2003; 4(8):1277–1287; doi: 10.1517/14656566.4.8.1277
50.
Wong-BeringerA, JacobsRA, GuglielmoBJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis, 1998; 27(3):603–618; doi: 10.1086/514704
51.
LooAS, MuhsinSA, WalshTJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf, 2013; 12(6):881–895; doi: 10.1517/14740338.2013.827168
52.
GallagherJC, Dodds AshleyES, DrewRH, et al.Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother, 2003; 4(2):147–164; doi: 10.1517/14656566.4.2.147
53.
Gallagher JC. Amphotericin B deoxycholate: Time to retire our old standard?. Expert Rev Anti Infect Ther, 2005; 3(3):313–316; doi: 10.1586/14787210.3.3.313
54.
SheikhN, JahagirdarV, KothadiaS, et al.Antifungal drug resistance in Candida species. Eur J Gen Med, 2013; 10(4):254–258; doi: 10.29333/ejgm/82217
55.
PerfectJR, GhannoumM. Emerging issues in antifungal resistance. Infect Dis Clin North Am, 2020; 34(4):921–943; doi: 10.1016/j.idc.2020.05.003
56.
FurukawaT, van RhijnN, FraczekM, et al.The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus. Nat Commun, 2020; 11(1):427; doi: 10.1038/s41467-019-14191-1
KalantarE, AssadiM, PormazaheriH, et al.Candida non albicans with a high amphotericin B resistance pattern causing candidemia among cancer patients. Asian Pac J Cancer Prev, 2014; 15(24):10933–10935; doi: 10.7314/APJCP.2014.15.24.10933
59.
WalshTJ, MelcherGP, RinaldiMG, et al.Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol, 1990; 28(7):1616–1622; doi: 10.1128/jcm.28.7.1616-1622.1990
60.
PoschW, BlatzerM, WilflingsederD, et al.Aspergillus terreus: Novel lessons learned on amphotericin B resistance. Med Mycol, 2018; 56(Suppl 1):73–82; doi: 10.1093/mmy/myx119
61.
BowerCPR, OxleyJD, CampbellCK, et al.Cutaneous Scedosporium apiospermum infection in an immunocompromised patient. J Clin Pathol, 1999; 52(11):846–848; doi: 10.1136/jcp.52.11.846
62.
Ostrosky-ZeichnerL, MarrKA, RexJH, et al.Amphotericin B: Time for a new “gold standard.”. Clin Infect Dis, 2003; 37(3):415–425; doi: 10.1086/376634
63.
YoungLY, HullCM, HeitmanJ. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother, 2003; 47(9):2717–2724; doi: 10.1128/AAC.47.9.2717-2724.2003
64.
McCarthyM, O'ShaughnessyEM, WalshTJ. Amphotericin B: Polyene Resistance Mechanisms. In: Antimicrobial Drug Resistance. (MayersD, SobelJ, OuelletteM, et al. eds.) Springer: Cham; 2017; pp. 387–395; doi: 10.1007/978-3-319-46718-4_26
AhmadS, JosephL, ParkerJE, et al.ERG6 and ERG2 are major targets conferring reduced susceptibility to amphotericin B in clinical Candida glabrata isolates in Kuwait. Antimicrob Agents Chemother, 2019; 63(2):e01900-18; doi: 10.1128/AAC.01900-18
69.
KellySL, LambDC, KellyDE, et al.Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Lett, 1997; 400(1):80–82; doi: 10.1016/S0014-5793(96)01360-9
70.
PinjonE, MoranGP, JacksonCJ, et al.Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother, 2003; 47(8):2424–2437; doi: 10.1128/AAC.47.8.2424-2437.2003
71.
VincentBM, LancasterAK, Scherz-ShouvalR, et al.Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol, 2013; 11(10):e1001692; doi: 10.1371/journal.pbio.1001692
72.
MartelCM, ParkerJE, BaderO, et al.A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother, 2010; 54(9):3578–3583; doi: 10.1128/AAC.00303-10
73.
KellySL, LambDC, TaylorM, et al.Resistance to amphotericin B associated with defective sterol Δ8 → 7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett, 1994; 122(1–2):39–42; doi: 10.1111/j.1574-6968.1994.tb07140.x
74.
Joseph-HorneT, LoefflerRST, HollomonDW, et al.Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J Med Vet Mycol, 1996; 34(3):223–225; doi: 10.1080/02681219680000381
75.
ForastieroA, Mesa-ArangoAC, Alastruey-IzquierdoA, et al.Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother, 2013; 57(10):4769–4781; doi: 10.1128/AAC.00477-13
76.
BalkanC, ErcanI, IsikE, et al.Genomewide elucidation of drug resistance mechanisms for systemically used antifungal drugs amphotericin B, caspofungin, and voriconazole in the budding yeast. Antimicrob Agents Chemother, 2019; 63(9):e02268-18; doi: 10.1128/AAC.02268-18
77.
Sokol-AndersonM, SlighJE, ElbergS, et al.Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother, 1988; 32(5):702–705; doi: 10.1128/AAC.32.5.702
78.
BlumG, HörtnaglC, JukicE, et al.New insight into amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother, 2013; 57(4):1583–1588; doi: 10.1128/AAC.01283-12
79.
CiriglianoA, MaconeA, BianchiMM, et al.Ergosterol reduction impairs mitochondrial DNA maintenance in S. cerevisiae. Biochim Biophys Acta Mol Cell Biol Lipids, 2019; 1864(3):290–303; doi: 10.1016/j.bbalip.2018.12.002
80.
SeoK, AkiyoshiH, OhnishiY. Alteration of cell wall composition leads to Amphotericin B resistance in Aspergillus flavus. Microbiol Immunol, 1999; 43(11):1017–1025.
81.
NettJE, CrawfordK, MarchilloK, et al.Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother, 2010; 54(8):3505–3508; doi: 10.1128/AAC.00227-10
82.
TaffHT, MitchellKF, EdwardJA, et al.Mechanisms of Candida biofilm drug resistance. Future Microbiol, 2013; 8(10):1325–1337; doi: 10.2217/fmb.13.101
83.
Mesa-ArangoAC, RuedaC, RománE, et al.Cell wall changes in amphotericin B-resistant strains from Candida tropicalis and relationship with the immune responses elicited by the host. Antimicrob Agents Chemother, 2016; 60(4):2326–2335; doi: 10.1128/AAC.02681-15
84.
BahmedK, BonalyR, WathierM, et al.Change of cell wall chitin content in amphotericin B resistant Kluyveromyces strains. FEMS Microbiol Lett, 2002; 216(1):99–103; doi: 10.1016/S0378-1097(02)01000-5
85.
ShivarathriR, JenullS, ChauhanM, et al.Comparative transcriptomics reveal possible mechanisms of amphotericin B resistance in Candida auris. Antimicrob Agents Chemother, 2022; 66(6):e0227621.
86.
ChakrabartiA, SinghS. Multidrug-resistant Candida auris: An epidemiological review. Expert Rev Anti Infect Ther, 2020; 18(6):551–562; doi: 10.1080/14787210.2020.1750368
87.
NavalkeleBD, RevankarS, ChandrasekarP. Candida auris: A worrisome, globally emerging pathogen. Expert Rev Anti Infect Ther, 2017; 15(9):819–827; doi: 10.1080/14787210.2017.1364992
88.
RybakJM, BarkerKS, MuñozJF, et al.In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris. Clin Microbiol Infect, 2022; 28(6):838–843; doi: 10.1016/j.cmi.2021.11.024
89.
SarmaS, KumarN, SharmaS, et al.Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol, 2013; 31(1):90–91; doi: 10.4103/0255-0857.108746
90.
MuñozJF, GadeL, ChowNA, et al.Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun, 2018; 9(1):5346; doi: 10.1038/s41467-018-07779-6
91.
EscandónP, ChowNA, CaceresDH, et al.Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis, 2019; 68(1):15–21; doi: 10.1093/cid/ciy411
92.
YadavA, SinghA, WangY, et al. Colonisation and transmission dynamics of Candida auris. among chronic respiratory diseases patients hospitalised in a chest hospital, Delhi, India: A comparative analysis of whole genome sequencing and microsatellite typing. J Fungi (Basel) 2021;7(2):81; doi: 10.3390/jof702, 0081
93.
SherryL, RamageG, KeanR, et al.Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis, 2017; 23(2):328–331; doi: 10.3201/eid2302.161320
94.
FunatoK, ValléeB, RiezmanH. Biosynthesis and trafficking of sphingolipids in the yeast Saccharomyces cerevisiae. Biochemistry, 2002; 41(51):15105–15114; doi: 10.1021/bi026616d
95.
Dickson RC. Thematic review series: Sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. J Lipid Res, 2008; 49(5):909–921; doi: 10.1194/jlr.r800003-jlr200
96.
BreslowDK, CollinsSR, BodenmillerB, et al.Orm family proteins mediate sphingolipid homeostasis. Nature, 2010; 463(7284):1048–1053; doi: 10.1038/nature08787
97.
SimsKJ, SpassievaSD, VoitEO, et al.Yeast sphingolipid metabolism: Clues and connections. Biochem Cell Biol, 2004; 82(1):45–61; doi: 10.1139/o03-086
98.
SchorlingS, ValléeB, BarzWP, et al.Lag1p and Lac1p are essential for the Acyl-CoA-dependent ceramide synthase reaction in Saccharomyces cerevisae. Mol Biol Cell, 2001; 12(11):3417–3427; doi: 10.1091/mbc.12.11.3417
99.
SkrzypekMS, NagiecMM, LesterRL, et al.Analysis of phosphorylated sphingolipid long-chain bases reveals potential roles in heat stress and growth control in Saccharomyces. J Bacteriol, 1999; 181(4):1134–1140; doi: 10.1128/jb.181.4.1134-1140.1999
100.
ZhouJ, SabaJD. Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. Biochem Biophys Res Commun, 1998; 242(3):502–507; doi: 10.1006/bbrc.1997.7993
101.
TidharR, FutermanAH. The complexity of sphingolipid biosynthesis in the endoplasmic reticulum. Biochim Biophys Acta Mol Cell Res, 2013; 1833(11):2511–2518; doi: 10.1016/j.bbamcr.2013.04.010
102.
KajiwaraK, IkedaA, Aguilera-RomeroA, et al.Osh proteins regulate COPII-mediated vesicular transport of ceramide from the endoplasmic reticulum in budding yeast. J Cell Sci, 2014; 127(2):376–387; doi: 10.1242/jcs.132001
103.
HechtbergerP, DaumG. Intracellular transport of inositol-containing sphingolipids in the yeast, Saccharomyces cerevisiae. FEBS Lett, 1995; 367(2):201–204; doi: 10.1016/0014-5793(95)00567-S
104.
HurstLR, FrattiRA. Lipid rafts, sphingolipids, and ergosterol in yeast vacuole fusion and maturation. Front Cell Dev Biol, 2020; 8:539; doi: 10.3389/fcell.2020.00539
105.
KumarM, SinghA, KumariS, et al.Sphingolipidomics of drug resistant Candida auris clinical isolates reveal distinct sphingolipid species signatures. Biochim Biophys Acta Mol Cell Biol Lipids, 2021; 1866(1):158815; doi: 10.1016/j.bbalip.2020.158815
106.
SharmaS, AlfatahM, BariVK, et al.Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. Antimicrob Agents Chemother, 2014; 58(4):2409–2414; doi: 10.1128/AAC.02130-13
107.
GaultCR, ObeidLM, HannunYA. An Overview of sphingolipid metabolism: From synthesis to breakdown. Adv Exp Med Biol, 2010; 688:1–23; doi: 10.1007/978-1-4419-6741-1_1
108.
Walther TC. Keeping sphingolipid levels nORMal. Proc Natl Acad Sci U S A, 2010; 107(13):5701–5702; doi: 10.1073/pnas.1001503107
109.
HanG, GuptaSD, GableK, et al.The ORMs interact with transmembrane domain 1 of Lcb1 and regulate serine palmitoyltransferase oligomerization, activity and localization. Biochim Biophys Acta Mol Cell Biol Lipids, 2019; 1864(3):245–259; doi: 10.1016/j.bbalip.2018.11.007
110.
RoelantsFM, BreslowDK, MuirA, et al.Protein kinase Ypk1 phosphorylates regulatory proteins Orm1 and Orm2 to control sphingolipid homeostasis in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A, 2011; 108(48):19222–19227; doi: 10.1073/pnas.1116948108
111.
van den HazelHB, PichlerH, do Valle MattaMA, et al.PDR16 and PDR17, two homologous genes of Saccharomyces cerevisiae, affect lipid biosynthesis and resistance to multiple drugs. J Biol Chem, 1999; 274(4):1934–1941; doi: 10.1074/jbc.274.4.1934
112.
KatsukiY, YamaguchiY, TaniM. Overexpression of PDR16 confers resistance to complex sphingolipid biosynthesis inhibitor aureobasidin A in yeast Saccharomyces cerevisiae. FEMS Microbiol Lett, 2018; 365(3):1–10; doi: 10.1093/femsle/fnx255
113.
ŠimováZ, PoloncováK, TahotnáD, et al.The yeast Saccharomyces cerevisiae Pdr16p restricts changes in ergosterol biosynthesis caused by the presence of azole antifungals. Yeast, 2013; 30(6):229–241; doi: 10.1002/yea.2956
114.
NavarreC, GoffeauA. Membrane hyperpolarization and salt sensitivity induced by deletion of PMP3, a highly conserved small protein of yeast plasma membrane. EMBO J, 2000; 19(11):2515–2524; doi: 10.1093/emboj/19.11.2515
115.
BariVK, SharmaS, AlfatahM, et al.Plasma membrane proteolipid 3 protein modulates amphotericin B resistance through sphingolipid biosynthetic pathway. Sci Rep, 2015; 5:9685; doi: 10.1038/srep09685
116.
de BlockJ, SzopinskaA, GuerriatB, et al.Yeast Pmp3p has an important role in plasma membrane organization. J Cell Sci, 2015; 128(19):3646–3659; doi: 10.1242/jcs.173211
117.
HuangZ, ChenK, ZhangJ, et al.A functional variomics tool for discovering drug-resistance genes and drug targets. Cell Rep, 2013; 3(2):577–585; doi: 10.1016/j.celrep.2013.01.019
118.
MukhopadhyayK, PrasadT, SainiP, et al.Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrob Agents Chemother, 2004; 48(5):1778–1787; doi: 10.1128/AAC.48.5.1778-1787.2004
119.
GuanXL, SouzaCM, PichlerH, et al.Functional interactions between sphingolipids and sterols in biological membranes regulating cell physiology. Mol Biol Cell, 2009; 20(7):2083–2095; doi: 10.1091/mbc.E08-11-1126
120.
VillasmilML, BankaitisVA, MousleyCJ. The oxysterol-binding protein superfamily: New concepts and old proteins. Biochem Soc Trans, 2012; 40(2):469–473; doi: 10.1042/BST20120012
121.
LeBlancMA, FairnGD, RussoSB, et al.The yeast oxysterol binding protein Kes1 maintains sphingolipid levels. PLoS One, 2013; 8(4):e60485; doi: 10.1371/journal.pone.0060485
122.
SwainE, BaudryK, StukeyJ, et al.Sterol-dependent regulation of sphingolipid metabolism in Saccharomyces cerevisiae. J Biol Chem, 2002; 277(29):26177–26184; doi: 10.1074/jbc.M204115200
PrasadT, SainiP, GaurNA, et al.Functional analysis of CaIPT1, a sphingolipid biosynthetic gene involved in multidrug resistance and morphogenesis of Candida albicans. Antimicrob Agents Chemother, 2005; 49(8):3442–3452; doi: 10.1128/AAC.49.8.3442-3452.2005
